Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

To join this study, participants must be between 12 and 80 years old and weigh at least 40 kg. You must have a confirmed diagnosis of EoE, meaning it has been identified through a previous examination and biopsy of your gullet.

You should be experiencing symptoms of EoE, specifically having difficulty swallowing (food feeling stuck or going down slowly) at least twice a week in the month leading up to the study. It's important that your diet has been stable for at least 8 weeks before starting the study and remains consistent throughout.

If you are currently taking other medications for EoE, asthma, or allergies, these generally need to have been on a stable dose for a certain period before the study begins. The team will review all your medical history and current treatments to ensure it's safe and appropriate for you to take part.

If you join this study, it will involve a screening period of 2 to 8 weeks to determine if you are suitable. Once eligible, you will enter a main treatment period lasting 52 weeks (about a year). During this time, you will receive injections under your skin, either the study medicine (Tezepelumab) or a placebo, at regular intervals. You won't know which one you are receiving.

After the 52-week treatment, you may have the option to continue receiving the active medicine for an additional 24 weeks in an 'extension period'. No matter whether you join the extension or not, there will be a 12-week safety follow-up period without treatment, where researchers will check in on your health. Throughout the study, you will have regular clinic visits, assessments, and tests to monitor your health and how the treatment is working. Approximately 360 people will take part in this study, with an equal chance of being assigned to one of three groups.